Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 7
2003 2
2004 3
2005 2
2009 4
2010 3
2011 3
2012 4
2013 2
2015 4
2016 3
2017 4
2018 5
2019 3
2020 4
2021 8
2022 5
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, Roberts C, Bishara M, Nice R, Lees CW, Sebastian S, Irving PM, Russell RK, McDonald TJ, Goodhand JR, Ahmad T, Kennedy NA; PANTS Consortium. Chanchlani N, et al. Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00044-X. doi: 10.1016/S2468-1253(24)00044-X. Online ahead of print. Lancet Gastroenterol Hepatol. 2024. PMID: 38640937 Free article.
Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.
Bai BYH, Reppell M, Smaoui N, Waring JF, Pivorunas V, Guay H, Lin S, Chanchlani N, Bewshea C, Goodhand JR, Kennedy NA, Ahmad T, Anderson CA; UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Bai BYH, et al. J Crohns Colitis. 2024 Mar 1;18(3):431-445. doi: 10.1093/ecco-jcc/jjad166. J Crohns Colitis. 2024. PMID: 37776235 Free PMC article.
Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity.
Asamoah-Boaheng M, Goldfarb D, Prusinkiewicz MA, Golding L, Karim ME, Barakauskas V, Wall N, Jassem AN, Marquez AC, MacDonald C, O'Brien SF, Lavoie P, Grunau B. Asamoah-Boaheng M, et al. Among authors: macdonald c. Cureus. 2023 Jan 31;15(1):e34465. doi: 10.7759/cureus.34465. eCollection 2023 Jan. Cureus. 2023. PMID: 36874687 Free PMC article.
70 results